Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › nirmatrelvir/ritonavir

nirmatrelvir/ritonavir

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of nirmatrelvir/ritonavir

3 trials tracked of nirmatrelvir/ritonavir.

3Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 1 3
  1. Phase 1 Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants. Completed
  2. Phase 1 A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin Completed
  3. Phase 1 Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Paxlovid prescription associated with 51% lower hospitalization risk in US adults with COVID-19
Infectious Disease
Paxlovid prescription associated with 51% lower hospitalization risk in US adults with COVID-19 Paxlovid prescription linked to lower hospitalization risk in adults with COVID-19
An observational study of eligible US adults with COVID-19 found those prescribed Paxlovid were 51% less likely to be hospitalized.
Adults prescribed Paxlovid for COVID-19 were 51% less likely to be hospitalized compared to those who did not get the medication.
CDC Apr 5, 2026